Erlotinib Completed Phase 2 Trials for Endometrial Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00030485Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer